Biomarkers for the Early Detection and Progression of Alzheimer's Disease

Counts, Scott E.; Ikonomovic, Milos D.; Mercado, Natosha; Vega, Irving E.; Mufson, Elliott J.

doi:10.1007/s13311-016-0481-z

Cited by 224Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCerebrospinal fluid and hydrocephalus

Biomarkers for the Early Detection and Progression of Alzheimer's Disease

Open access

Counts, Scott E., Ikonomovic, Milos D., Mercado, Natosha, Vega, Irving E., Mufson, Elliott J.·2017·Neurotherapeutics

DOI 10.1007/s13311-016-0481-zPMC PMC5233625

Open this paper in CoChat — free account Open PDF

Abstract

The recent failures of potential disease-modifying drugs for Alzheimer's disease (AD) may reflect the fact that the enrolled participants in clinical trials are already too advanced to derive a clinical benefit. Thus, well-validated biomarkers for the early detection and accurate diagnosis of the preclinical stages of AD will be crucial for therapeutic advancement. The combinatorial use of biomarkers derived from biological fluids, such as cerebrospinal fluid (CSF), with advanced molecular imaging and neuropsychological testing may eventually achieve the diagnostic sensitivity and specificity necessary to identify people in the earliest stages of the disease when drug modification is most likely possible. In this regard, positive amyloid or tau tracer retention on positron emission tomography imaging, low CSF concentrations of the amyloid-β 1-42 peptide, high CSF concentrations in total tau and phospho-tau, mesial temporal lobe atrophy on magnetic resonance imaging, and temporoparietal/precuneus hypometabolism or hypoperfusion on 18F-fluorodeoxyglucose positron emission tomography have all emerged as biomarkers for the progression to AD. However, the ultimate AD biomarker panel will likely involve the inclusion of novel CSF and blood biomarkers more precisely associated with confirmed pathophysiologic mechanisms to improve its reliability for detecting preclinical AD. This review highlights advancements in biological fluid and imaging biomarkers that are moving the field towards achieving the goal of a preclinical detection of AD.

Integrity signals

Registry

Crossref · 10.1007/s13311-016-0481-z

Cites

294 of 294 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Aβ began to accumulate up to 15-20 years prior to clinical symptoms of Alzheimer's disease.
“Previous studies revealed that Aβ began to accumulate up to 15–20 years prior to clinical symptoms of Alzheimer’s disease42,43.”
From Integrated algorithm combining plasma biomarkers and cognitive assessments accurately predicts brain β-amyloid pathology (2023) · cites this paper as [43]

Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y., Jiang, Q. L., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,351 · see citing works
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · see citing works
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · see citing works
Induction of the Vitamin D Receptor Attenuates Autophagy Dysfunction-Mediated Cell Death Following Traumatic Brain Injury
Cui, C., Cui, J., Jin, F., Cui, Y., Li, R., Jiang, X., Tian, Y., Wang, R. C., Jiang, P., & Gao, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479571 · Cited by 5,214 · see citing works
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · see citing works
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · see citing works
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347 · see citing works
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490 · see citing works
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · see citing works
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668 · see citing works
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065 · see citing works
The role of autophagy in neurodegenerative disease
Nixon, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3232 · Cited by 2,059 · see citing works
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049 · see citing works
The carboxy terminus of the .beta. amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease
Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022 · see citing works
Mild Cognitive Impairment Represents Early-Stage Alzheimer Disease
Morris, J. C., Storandt, M., Miller, J. P., McKeel, D. W., Price, J. L., Rubin, E. H., & Berg, L. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.397 · Cited by 1,833 · see citing works
Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774 · see citing works
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731 · see citing works
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · see citing works
Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · see citing works
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment
Jack, C. R., Petersen, R. C., Xu, Y. C., O’Brien, P. C., Smith, G. E., Ivnik, R. J., Boeve, B. F., Waring, S. C., Tangalos, E. G., & Kokmen, E. (1999) · Neurology · doi:10.1212/wnl.52.7.1397 · Cited by 1,404 · see citing works
Preclinical Evidence of Alzheimer's Disease in Persons Homozygous for the ε4 Allele for Apolipoprotein E
Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366 · see citing works
Neuropathology of older persons without cognitive impairment from two community-based studies
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., & Wilson, R. S. (2006) · Neurology · doi:10.1212/01.wnl.0000219668.47116.e6 · Cited by 1,336 · see citing works
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246 · see citing works
PET Imaging of Tau Deposition in the Aging Human Brain
Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214 · see citing works
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176 · see citing works
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117 · see citing works
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104 · see citing works
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048 · see citing works
Natural history of mild cognitive impairment in older persons
Bennett, D. A., Wilson, R. S., Schneider, J. A., Evans, D. A., Beckett, L. A., Aggarwal, N. T., Barnes, L. L., Fox, J. H., & Bach, J. (2002) · Neurology · doi:10.1212/wnl.59.2.198 · Cited by 1,037 · see citing works
[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036 · see citing works
Plasma phospholipids identify antecedent memory impairment in older adults
Mapstone, M. E., Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., et al. (2014) · Nature Medicine · doi:10.1038/nm.3466 · Cited by 1,031 · see citing works
The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Weiner, M. W., Veitch, D. P., Aisen, P. S. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Liu, E., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.05.1769 · Cited by 1,011 · see citing works
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986 · see citing works
Tau positron emission tomographic imaging in aging and early <scp>A</scp> lzheimer disease
Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986 · see citing works
Synthesis and Evaluation of 11C-Labeled 6-Substituted 2-Arylbenzothiazoles as Amyloid Imaging Agents
Mathis, C. A., Wang, Y., Holt, D. P., Huang, G.-F., Debnath, M. L., & Klunk, W. E. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030026b · Cited by 976 · see citing works
Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case‐control study
Fiandaca, M. S., Kapogiannis, D., Mapstone, M., Boxer, A., Eitan, E., Schwartz, J. B., Abner, E. L., Petersen, R. C., Federoff, H. J., Miller, B. L., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.008 · Cited by 959 · see citing works
Rates of hippocampal atrophy correlate with change in clinical status in aging and AD
Jack, C. R., Petersen, R. C., Xu, Y., O’Brien, P. C., Smith, G. E., Ivnik, R. J., Boeve, B. F., Tangalos, E. G., & Kokmen, E. (2000) · Neurology · doi:10.1212/wnl.55.4.484 · Cited by 937 · see citing works
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933 · see citing works
Cerebrospinal Fluid tau/β-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · see citing works
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease
Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22248 · Cited by 833 · see citing works
APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830 · see citing works
Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090106797 · Cited by 790 · see citing works
tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease?
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789 · see citing works
-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease
Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L., & Rowe, C. C. (2007) · Brain · doi:10.1093/brain/awm238 · Cited by 789 · see citing works
Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease
Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900345106 · Cited by 785 · see citing works
Apolipoprotein E Status as a Predictor of the Development of Alzheimer's Disease in Memory-Impaired Individuals
Petersen, R. C. (1995) · JAMA · doi:10.1001/jama.1995.03520400044042 · Cited by 783 · see citing works
Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease
Höck, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Müller-Tillmanns, B., Lemke, U., Henke, K., Moritz, E., Garcia, E., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00294-0 · Cited by 777 · see citing works
Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls
Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.-R., Trojanowski, J. Q., Lee, V. M.-Y., Ono, M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.037 · Cited by 760 · see citing works
Hippocampal and entorhinal atrophy in mild cognitive impairment
Devanand, D. P., Pradhaban, G., Liu, X., Khandji, A., Santi, S. D., Segal, S., Rusinek, H., Pelton, G. H., Honig, L. S., Mayeux, R. P., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000256697.20968.d7 · Cited by 739 · see citing works
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2362 · Cited by 734 · see citing works
PET imaging of amyloid deposition in patients with mild cognitive impairment
Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A. E., Ringheim, A., Långström, B., & Nordberg, A. K. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.03.029 · Cited by 725 · see citing works
In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18 F-AV-45 (Flobetapir F 18)
Wong, D. F., Rosenberg, P. B., Zhou, Y., Kumar, A., Raymont, V., Ravert, H. T., Dannals, R. F., Nandi, A., Brašić, J. R., Ye, W., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069088 · Cited by 684 · see citing works
Episodic memory loss is related to hippocampal-mediated -amyloid deposition in elderly subjects
Mormino, E. C., Kluth, J. T., Madison, C. M., Rabinovici, G. D., Baker, S. L., Miller, B. L., Koeppe, R. A., Mathis, C. A., Weiner, M. W., Jagust, W. J., et al. (2009) · Brain · doi:10.1093/brain/awn320 · Cited by 684 · see citing works
Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808
Chien, D. T., Szardenings, A. K., Bahri, S., Walsh, J. C., Mu, F., Xia, C. A., Shankle, W. R., Lerner, A. J., Su, M., Elizarov, A. M., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130098 · Cited by 676 · see citing works
Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism
Rowe, C. C., Ackerman, U., Browne, W. F., Mulligan, R. S., Pike, K. E., O'Keefe, G. J., Tochon‐Danguy, H., Chan, G., Berlangieri, S. U., Jones, G. R., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70001-2 · Cited by 671 · see citing works
Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia
Buchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664 · see citing works
Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease: Differences Between Early- and Late-Onset Alzheimer Disease and Stability During the Course of Disease
Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660 · see citing works
Decreased β-Amyloid1-42and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease
Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656 · see citing works
Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807
Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122059 · Cited by 651 · see citing works
18 F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial
Vandenberghe, R. R., Laere, K. V., Ivanoiu, A., Salmon, É., Bastin, C., Triau, E., Hasselbalch, S. G., Law, I. G., Andersen, A., Kørner, A., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22068 · Cited by 649 · see citing works
Validating novel tau positron emission tomography tracer <scp>[F‐18]‐AV‐1451 (T807)</scp> on postmortem brain tissue
Marquié, M., Normandin, M. D., Vanderburg, C. R., Costantino, I. M., Bien, E. A., Rycyna, L. G., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M. L., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24517 · Cited by 615 · see citing works
FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease
Foster, N. L., Heidebrink, J. L., Clark, C. M., Jagust, W. J., Arnold, S. E., Barbas, N. R., DeCarli, C. S., Scott Turner, R., Koeppe, R. A., Higdon, R., et al. (2007) · Brain · doi:10.1093/brain/awm177 · Cited by 608 · see citing works
[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605 · see citing works
Mild cognitive impairment
Chételat, G., Desgranges, B., Sayette, V. D. L., Viader, F., Eustache, F., & Baron, J. (2003) · Neurology · doi:10.1212/01.wnl.0000055847.17752.e6 · Cited by 604 · see citing works
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study
Sabri, O., Sabbagh, M. N., Seibyl, J., Barthel, H., Akatsu, H., Ouchi, Y., Senda, K., Murayama, S., Ishii, K., Takao, M., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.004 · Cited by 602 · see citing works
Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study
Barthel, H., Gertz, H., Dresel, S. H. J., Peters, O., Bartenstein, P., Büerger, K., Hiemeyer, F. J., Wittemer‐Rump, S., Seibyl, J. P., Reininger, C. B., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70077-1 · Cited by 588 · see citing works
Increase of Brain Oxidative Stress in Mild Cognitive Impairment
Praticò, D., Clark, C. M., Liun, F., Lee, V., & Trojanowski, J. Q. (2002) · Archives of Neurology · doi:10.1001/archneur.59.6.972 · Cited by 587 · see citing works
Plasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer Disease
Mehta, P. D., Pirttilä, T., Mehta, S. P., Sersen, E. A., Aisen, P. S., & Wisniewski, H. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.1.100 · Cited by 582 · see citing works
Conversion of Mild Cognitive Impairment to Alzheimer Disease Predicted by Hippocampal Atrophy Maps
Apostolova, L. G., Dutton, R. A., Dinov, I. D., Hayashi, K. M., Toga, A. W., Cummings, J. L., & Thompson, P. M. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.693 · Cited by 553 · see citing works
Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort
Risacher, S., Saykin, A., Wes, J., Shen, L., Firpi, H., & McDonald, B. (2009) · Current Alzheimer Research · doi:10.2174/156720509788929273 · Cited by 538 · see citing works
Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions
Bennett, D. A., Schneider, J. A., Bienias, J. L., Evans, D. A., & Wilson, R. S. (2005) · Neurology · doi:10.1212/01.wnl.0000152982.47274.9e · Cited by 537 · see citing works
YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease
Craig-Schapiro, R., Perrin, R. J., Roe, C. M., Xiong, C., Carter, D., Cairns, N. J., Mintun, M. A., Peskind, E. R., Li, G., Galasko, D. R., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.025 · Cited by 504 · see citing works
Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes.
Vinters, H. V., & Gilbert, J. J. (1983) · Stroke · doi:10.1161/01.str.14.6.924 · Cited by 504 · see citing works
Imaging of amyloid burden and distribution in cerebral amyloid angiopathy
Johnson, K. A., Gregas, M., Becker, J. A., Kinnecom, C., Salat, D. H., Moran, E. K., Smith, E. E., Rosand, J., Rentz, D. M., Klunk, W. E., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21164 · Cited by 495 · see citing works
Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression
Zetterberg, H., Skillbäck, T., Mattsson, N., Trojanowski, J. Q., Portelius, E., Shaw, L. M., Weiner, M. W., Blennow, K., & Initiative, F. T. A. D. N. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3037 · Cited by 487 · see citing works
Cerebrospinal fluid protein biomarkers for Alzheimer’s disease
Blennow, K. (2004) · Neurotherapeutics · doi:10.1602/neurorx.1.2.213 · Cited by 487 · see citing works
Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization
Vanmechelen, E., Vanderstichele, H., Davidsson, P., Kerschaver, E. V., Perre, B. V. D., Sjögren, M. J. C., Andreasen, N. C., & Blennow, K. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01036-3 · Cited by 487 · see citing works
The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease.
Fahnestock, M., Michalski, B., Xu, B., & Coughlin, M. (2001) · Molecular and cellular neurosciences · doi:10.1006/mcne.2001.1016 · Cited by 482 · see citing works
An autoradiographic evaluation of AV-1451 Tau PET in dementia
Lowe, V. J., Curran, G., Fang, P., Liesinger, A. M., Josephs, K. A., Parisi, J. E., Kantarci, K., Boeve, B. F., Pandey, M. K., Bruinsma, T., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0315-6 · Cited by 474 · see citing works
Regional Cerebral Metabolic Alterations in Dementia of the Alzheimer Type
Friedland, R. P., Budinger, T. F., Ganz, E., Yano, Y., Mathis, C. A., Koss, B., Ober, B. A., Huesman, R. H., & Derenzo, S. (1983) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-198308000-00003 · Cited by 468 · see citing works
Neuropathologic Substrate of Mild Cognitive Impairment
Markesbery, W. R., Schmitt, F. A., Kryscio, R. J., Davis, D. G., Smith, C. D., & Wekstein, D. R. (2006) · Archives of Neurology · doi:10.1001/archneur.63.1.38 · Cited by 460 · see citing works
Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease
Blennow, K., Dubois, B., Fagan, A. M., Lewczuk, P., de Leon, M. J., & Hampel, H. J. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.02.004 · Cited by 455 · see citing works
Association of Low Plasma Aβ42/Aβ40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease
Graff‐Radford, N. R., Crook, J. E., Lucas, J. A., Boeve, B. F., Knopman, D. S., Ivnik, R. J., Smith, G. E., Younkin, L. H., Petersen, R. C., & Younkin, S. G. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.354 · Cited by 441 · see citing works
Plasma Aβ40 and Aβ42 and Alzheimer’s disease: Relation to age, mortality, and risk
Mayeux, R., Honig, L. S., Tang, M.-X., Manly, J., Stern, Y., Schupf, N., & Mehta, P. D. (2003) · Neurology · doi:10.1212/01.wnl.0000091890.32140.8f · Cited by 434 · see citing works
Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease
Doecke, J. D. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1282 · Cited by 420 · see citing works
Dissecting phenotypic traits linked to human resilience to Alzheimer’s pathology
Perez-Nievas, B. G., Stein, T. D., Tai, H.-C., Dols-Icardo, O., Scotton, T. C., Barroeta-Espar, I., Fernandez-Carballo, L., de Munain, E. L., Perez, J., Marquie, M., et al. (2013) · Brain · doi:10.1093/brain/awt171 · Cited by 387 · see citing works
Plasma tau levels in Alzheimer's disease
Zetterberg, H., Wilson, D. H., Andréasson, U., Minthon, L., Blennow, K., Randall, J., & Hansson, O. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt163 · Cited by 385 · see citing works
Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
Palmqvist, S., Zetterberg, H., Mattsson, N., Johansson, P., Initiative, F. T. A. D. N., Minthon, L., Blennow, K., Olsson, M., For the Swedish BioFINDER study group, Hansson, O., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001991 · Cited by 375 · see citing works
Amyloid Imaging with18F-Florbetaben in Alzheimer Disease and Other Dementias
Villemagne, V. L., Ong, K. T., Mulligan, R. S., Holl, G., Pejoska, S., Jones, G. R., O'Keefe, G. J., Ackerman, U., Tochon‐Danguy, H., Chan, J. G., et al. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.089730 · Cited by 374 · see citing works
Relationship between atrophy and β‐amyloid deposition in Alzheimer disease
Chételat, G., Villemagne, V. L., Bourgeat, P., Pike, K. E., Jones, G., Ames, D., Ellis, K. A., Szoeke, C., Martins, R. N., O'Keefe, G. J., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21955 · Cited by 373 · see citing works
Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer Disease
Fleisher, A. S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.150 · Cited by 364 · see citing works
2014 Update of the Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.001 · Cited by 348 · see citing works
MCI conversion to dementia and the APOE genotype
Mosconi, L., Perani, D., Sorbi, S., Herholz, K., Nacmias, B., Holthoff‐Detto, V., Salmon, É., Baron, J., Cristofaro, M. T. D., Padovani, A., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000147469.18313.3b · Cited by 344 · see citing works
Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report.
Bacskai, B. J., Frosch, M. P., Freeman, S. H., Raymond, S. B., Augustinack, J. C., Johnson, K. A., Irizarry, M. C., Klunk, W. E., Mathis, C. A., DeKosky, S. T., et al. (2007) · PubMed · doi:10.1001/archneur.64.3.431 · Cited by 341 · see citing works
Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease
Kvartsberg, H., Duits, F. H., Ingelsson, M., Andreasen, N., Öhrfelt, A., Andersson, K., Brinkmalm, G., Lannfelt, L., Minthon, L., Hansson, O., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.10.009 · Cited by 339 · see citing works
Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density
Curtis, C., Gamez, J. E., Singh, U., Sadowsky, C. H., Villena, T., Sabbagh, M. N., Beach, T. G., Duara, R., Fleisher, A. S., Frey, K. A., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4144 · Cited by 332 · see citing works
Phase 1 Study of the Pittsburgh Compound B Derivative 18 F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease
Nelissen, N., Laere, K. V., Thurfjell, L., Owenius, R., Vandenbulcke, M., Koole, M. J. B., Bormans, G. M., Brooks, D. J., & Vandenberghe, R. R. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.063305 · Cited by 331 · see citing works
18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease
Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Tago, T., Hiraoka, K., Watanuki, S., Shidahara, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.164848 · Cited by 330 · see citing works
MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD
deToledo‐Morrell, L., Stoub, T. R., Bulgakova, M., Wilson, R. S., Bennett, D. A., Leurgans, S. E., Wuu, J., & Turner, D. A. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.007 · Cited by 324 · see citing works
Heterogeneity of Brain Glucose Metabolism in Mild Cognitive Impairment and Clinical Progression to Alzheimer Disease
Anchisi, D., Borroni, B., Franceschi, M., Kerrouche, N., Kalbe, E., Beuthien-Beumann, B., Cappa, S. F., Lenz, O., Lüdecke, S., Marcone, A., et al. (2005) · Archives of Neurology · doi:10.1001/archneur.62.11.1728 · Cited by 320 · see citing works
Intravenous immunoglobulins containing antibodies against -amyloid for the treatment of Alzheimer's disease
Dodel, R. C. (2004) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.033399 · Cited by 317 · see citing works
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects
Trojanowski, J. Q., Vandeerstichele, H., Korecka, M., Clark, C. M., Aisen, P. S. S., Petersen, R. C., Blennow, K., Soares, H. D., Simon, A. J., Lewczuk, P., et al. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.03.008 · Cited by 308 · see citing works
PET amyloid ligand [ 11 C]PIB uptake is increased in mild cognitive impairment
Kemppainen, N. M., Aalto, S., Wilson, I. A., Någren, K., Helin, S., Brück, A., Oikonen, V., Kailajärvi, M., Scheinin, M., Viitanen, M. H., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000260969.94695.56 · Cited by 306 · see citing works
Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease
Puchades, M. A., Hansson, S., Nilsson, C. L., Andreasen, N., Blennow, K., & Davidsson, P. (2003) · Molecular Brain Research · doi:10.1016/j.molbrainres.2003.08.005 · Cited by 306 · see citing works
Cognitive Decline and Brain Volume Loss as Signatures of Cerebral Amyloid-β Peptide Deposition Identified With Pittsburgh Compound B
Storandt, M., Mintun, M. A., Head, D. M., & Morris, J. C. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.272 · Cited by 304 · see citing works
PIB is a non-specific imaging marker of amyloid-beta (A ) peptide-related cerebral amyloidosis
Lockhart, A., Lamb, J. R., Osredkar, T., Sue, L. I., Joyce, J. N., Ye, L., Libri, V., Leppert, D., & Beach, T. G. (2007) · Brain · doi:10.1093/brain/awm191 · Cited by 302 · see citing works
Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment
Arnáiz, E., Jelic, V., Almkvist, O., Wahlund, L.-O., Winblad, B., Valind, S., & Nordberg, A. (2001) · Neuroreport · doi:10.1097/00001756-200103260-00045 · Cited by 302 · see citing works
The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean?
Duits, F. H., Teunissen, C. E., Bouwman, F. H., Visser, P. J., Mattsson, N., Zetterberg, H., Blennow, K., Hansson, O., Minthon, L., Andreasen, N., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.12.023 · Cited by 300 · see citing works
What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?
Jagust, W. J., Reed, B., Mungas, D., Ellis, W. G., & DeCarli, C. S. (2007) · Neurology · doi:10.1212/01.wnl.0000269790.05105.16 · Cited by 299 · see citing works
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI
Initiative, T. A. D. N., Shaw, L. M. J., Vanderstichele, H., Knapik-Czajka, M. E., Figurski, M., Coart, E., Blennow, K., Soares, H. D., Simon, A. J., Lewczuk, P., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0808-0 · Cited by 297 · see citing works
Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy
Wang, L. Y., Benzinger, T. L. S., Su, Y., Christensen, J. J., Friedrichsen, K. A., Aldea, P., McConathy, J., Cairns, N. J., Fagan, A. M., Morris, J. C., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2078 · Cited by 295 · see citing works
Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age
Sutphen, C. L., Jasielec, M. S., Shah, A. R., Macy, E. M., Xiong, C., Vlassenko, A. G., Benzinger, T. L. S., Stoops, E., Vanderstichele, H., Brix, B., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1285 · Cited by 294 · see citing works
Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers
Initiative, T. A. D. N., Landau, S. M., Thomas, B. A., Thurfjell, L., Schmidt, M. E., Margolin, R. A., Mintun, M. A., Pontecorvo, M. J., Baker, S. L., & Jagust, W. J. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2753-3 · Cited by 294 · see citing works
SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease
Brinkmalm, A., Brinkmalm, G., Honer, W. G., Frölich, L., Hausner, L., Minthon, L., Hansson, O., Wallin, A., Zetterberg, H., Blennow, K., et al. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-53 · Cited by 293 · see citing works
Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease
Villemagne, V. L., Pike, K. E., Darby, D., Maruff, P. T., Savage, G. R., Ng, S., Ackermann, U., Cowie, T., Currie, J. N., Chan, S. G., et al. (2008) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2008.02.008 · Cited by 291 · see citing works
Preclinical Alzheimer disease—the challenges ahead
Sperling, R. A., Karlawish, J., & Johnson, K. A. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.241 · Cited by 291 · see citing works
Guidelines for the standardization of preanalytic variables for blood‐based biomarker studies in Alzheimer's disease research
O’Bryant, S. E., Gupta, V. B., Henriksen, K., Edwards, M., Jeromin, A., Lista, S., Bazenet, C. E., Soares, H. D., Lovestone, S., Hampel, H. J., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.08.099 · Cited by 290 · see citing works
Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [ 11 C]PiB
Resnick, S. M., Sojkova, J., Zhou, Y., An, Y., Ye, W., Holt, D. P., Dannals, R. F., Mathis, C. A., Klunk, W. E., Ferrucci, L., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d3e3e9 · Cited by 288 · see citing works
Increased metabolic vulnerability in early-onset Alzheimer’s disease is not related to amyloid burden
Rabinovici, G. D., Furst, A. J., Alkalay, A., Racine, C. A., O’Neil, J. P., Janabi, M., Baker, S. L., Agarwal, N., Bonasera, S. J., Mormino, E. C., et al. (2010) · Brain · doi:10.1093/brain/awp326 · Cited by 280 · see citing works
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease
Portelius, E., Zetterberg, H., Skillbäck, T., Törnqvist, U., Andreasson, U., Trojanowski, J. Q., Weiner, M. W., Shaw, L. M., & Mattsson, N. (2015) · Brain · doi:10.1093/brain/awv267 · Cited by 279 · see citing works
Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease
Li, Y., Rinne, J. O., Mosconi, L., Pirraglia, E., Rusinek, H., DeSanti, S., Kemppainen, N., Någren, K., Kim, B.-C., Tsui, W., et al. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0833-y · Cited by 278 · see citing works
Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid
Grimmer, T., Riemenschneider, M., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Shiga, T., Wester, H.-J., Kurz, A., & Drzezga, A. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.027 · Cited by 278 · see citing works
Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.
Drzezga, A. E., Grimmer, T., Riemenschneider, M., Lautenschlager, N. T., Siebner, H. R., Alexopoulus, P., Minoshima, S., Schwaiger, M., & Kurz, A. (2005) · PubMed · Cited by 277 · see citing works
Longitudinal MRI atrophy biomarkers: Relationship to conversion in the ADNI cohort
Risacher, S. L., Shen, L., West, J. D., Kim, S., McDonald, B. C., Beckett, L. A., Harvey, D. J., Jack, C. R., Weiner, M. W., & Saykin, A. J. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.029 · Cited by 276 · see citing works
Biomarkers of Alzheimer disease in plasma
Irizarry, M. C. (2004) · NeuroRx · doi:10.1602/neurorx.1.2.226 · Cited by 269 · see citing works
Tau PET in Alzheimer disease and mild cognitive impairment
Cho, H., Choi, J. Y., Hwang, M. S., Lee, J., Kim, Y. J., Lee, H., Lyoo, C. H., Ryu, Y. H., & Lee, M. S. (2016) · Neurology · doi:10.1212/wnl.0000000000002892 · Cited by 267 · see citing works
Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET
Okamura, N., Furumoto, S., Fodero‐Tavoletti, M. T., Mulligan, R. S., Harada, R., Yates, P. A., Pejoska, S., Kudo, Y., Masters, C. L., Yanai, K., et al. (2014) · Brain · doi:10.1093/brain/awu064 · Cited by 266 · see citing works
Dissociating atrophy and hypometabolism impact on episodic memory in mild cognitive impairment
Chetelat, G. (2003) · Brain · doi:10.1093/brain/awg196 · Cited by 264 · see citing works
CSF Multianalyte Profile Distinguishes Alzheimer and Parkinson Diseases
Zhang, J., Sokal, I., Peskind, E. R., Quinn, J. F., Jankovic, J. J., Kenney, C., Chung, K. A., Millard, S. P., Nutt, J. G., & Montine, T. J. (2008) · American Journal of Clinical Pathology · doi:10.1309/w01y0b808emeh12l · Cited by 263 · see citing works
CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival
Skillbäck, T., Farahmand, B., Bartlett, J. W., Rosén, C., Mattsson, N., Nägga, K., Kilander, L., Religa, D., Wimo, A., Winblad, B., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000001015 · Cited by 263 · see citing works
Microarray Analysis of Hippocampal CA1 Neurons Implicates Early Endosomal Dysfunction During Alzheimer's Disease Progression
Ginsberg, S. D., Alldred, M. J., Counts, S., Cataldo, A. M., Neve, R. L., Jiang, Y., Wuu, J., Chao, M. V., Mufson, E. J., Nixon, R. A., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.030 · Cited by 257 · see citing works
Self-citation
CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects
Büerger, K., Teipel, S. J., Zinkowski, R. P., Blennow, K., Arai, H., Engel, R. R., Hofmann‐Kiefer, K., McCulloch, C., Ptok, U., Heun, R., et al. (2002) · Neurology · doi:10.1212/wnl.59.4.627 · Cited by 255 · see citing works
Increased CSF F 2 -isoprostane concentration in probable AD
Montine, T. J., Beal, M. F., Cudkowicz, M., O’Donnell, H., Margolin, R. A., McFarland, L. L., Bachrach, A., Zackert, W. E., Roberts, L. J., & Morrow, J. D. (1999) · Neurology · doi:10.1212/wnl.52.3.562 · Cited by 251 · see citing works
Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment
Camus, V., Payoux, P., Barré, L., Desgranges, B., Voisin, T., Tauber, C., Joie, R. L., Tafani, M., Hommet, C., Chételat, G., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2021-8 · Cited by 250 · see citing works
Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls
Morra, J. H., Tu, Z., Apostolova, L. G., Green, A. E., Avedissian, C., Madsen, S. K., Parikshak, N., Toga, A. W., Jack, C. R., Schuff, N. W., et al. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.10.043 · Cited by 241 · see citing works
Basal Cerebral Metabolism May Modulate the Cognitive Effects of Aβ in Mild Cognitive Impairment: An Example of Brain Reserve
Cohen, A. D., Price, J. C., Weissfeld, L. A., James, J. A., Rosario, B. L., Bi, W., Nebes, R. D., Saxton, J. A., Snitz, B. E., Aizenstein, H. J., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.3669-09.2009 · Cited by 240 · see citing works
Entorhinal Cortex β-Amyloid Load in Individuals with Mild Cognitive Impairment
Mufson, E. J., Chen, E.-Y., Cochran, E. J., Beckett, L. A., Bennett, D. A., & Kordower, J. H. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7086 · Cited by 237 · see citing works
Self-citation
MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease
Denk, J., Boelmans, K., Siegismund, C., Lassner, D., Arlt, S., & Jahn, H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126423 · Cited by 236 · see citing works
Increased proNGF Levels in Subjects with Mild Cognitive Impairment and Mild Alzheimer Disease
Peng, S., Wuu, J., Mufson, E. J., & Fahnestock, M. L. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.6.641 · Cited by 236 · see citing works
Self-citation
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease
Hu, W. T., Holtzman, D. M., Fagan, A. M., Shaw, L. M. J., Perrin, R. J., Arnold, S. E., Grossman, M., Xiong, C., Craig‐Schapiro, R., Clark, C. M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318266fa70 · Cited by 234 · see citing works
Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve.
Fotenos, A. F., Mintun, M., Snyder, A., Morris, J., & Buckner, R. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.27 · Cited by 228 · see citing works
Cerebrospinal Fluid Biomarkers and Rate of Cognitive Decline in Very Mild Dementia of the Alzheimer Type
Snider, B. J., Fagan, A. M., Roe, C. M., Shah, A. R., Grant, E., Xiong, C., Morris, J. C., & Holtzman, D. M. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.55 · Cited by 227 · see citing works
Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease
Vigo‐Pelfrey, C., Seubert, P., Barbour, R., Blomquist, C., Lee, M., Lee, D., Coria, F., Chang, L., Miller, B. L., Lieberburg, I. M., et al. (1995) · Neurology · doi:10.1212/wnl.45.4.788 · Cited by 225 · see citing works
The Role of Nerve Growth Factor Receptors in Cholinergic Basal Forebrain Degeneration in Prodromal Alzheimer Disease
Counts, S., & Mufson, E. J. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.4.263 · Cited by 223 · see citing works
Self-citation
Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease
Tarawneh, R. M., D’Angelo, G., Crimmins, D. L., Herries, E. M., Griest, T. A., Fagan, A. M., Zipfel, G. J., Ladenson, J. H., Morris, J. C., & Holtzman, D. M. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0086 · Cited by 219 · see citing works
Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence
Garibotto, V., Borroni, B., Kalbe, E., Herholz, K., Salmon, E., Holtoff, V., Sorbi, S., Cappa, S. F., Padovani, A., Fazio, F., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000327670.62378.c0 · Cited by 218 · see citing works
Cerebrospinal Fluid Tau and β-Amyloid 42 Proteins Identify Alzheimer Disease in Subjects With Mild Cognitive Impairment
Riemenschneider, M. J., Lautenschlager, N. T., Wagenpfeil, S., Diehl, J., Drzezga, A. E., & Kurz, A. (2002) · Archives of Neurology · doi:10.1001/archneur.59.11.1729 · Cited by 212 · see citing works
Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer’s disease and mild cognitive impairment
Mattsson, N., Tosun, D., Insel, P. S., Simonson, A., Jack, C. R., Beckett, L. A., Donohue, M., Jagust, W., Schuff, N. W., & Weiner, M. W. (2014) · Brain · doi:10.1093/brain/awu043 · Cited by 211 · see citing works
Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients.
Nostrand, W. E. V., Wagner, S. L., Shankle, W. R., Farrow, J. S., Dick, M. B., Rozemüller, A. J. M., Kuiper, M. A., Wolters, E. C., Zimmerman, J. B., & Cotman, C. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2551 · Cited by 205 · see citing works
Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to β-amyloid peptide42
Maddalena, A., Papassotiropoulos, A., Müller-Tillmanns, B., Jung, H. H., Hegi, T., Nitsch, R. M., & Hock, C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.9.1202 · Cited by 204 · see citing works
Absence of Pittsburgh Compound B Detection of Cerebral Amyloid β in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer Disease
Cairns, N. J., Ikonomović, M. D., Benzinger, T. L. S., Storandt, M., Fagan, A. M., Shah, A. R., Taylor‐Reinwald, L., Carter, D. R., Felton, A., Holtzman, D. M., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.279 · Cited by 203 · see citing works
Plasma Concentrations of Vitamins A and E and Carotenoids in Alzheimer's Disease
Zaman, Z., ROCHE, S., FIELDEN, P., Frost, P., Niriella, D. C., & CAYLEY, A. C. D. (1992) · Age and Ageing · doi:10.1093/ageing/21.2.91 · Cited by 202 · see citing works
Early detection of Alzheimer's disease using PiB and FDG PET
Cohen, A. D., & Klunk, W. E. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.001 · Cited by 202 · see citing works
Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer’s disease
Drzezga, A. E., Grimmer, T., Henriksen, G., Stangier, I., Perneczky, R., Diehl‐Schmid, J., Mathis, C. A., Klunk, W. E., Price, J. C., & DeKosky, S. T. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.09.020 · Cited by 202 · see citing works
Metabolomics of Human Brain Aging and Age-Related Neurodegenerative Diseases
Jové, M., Portero-Otín, M., Naudí, A., Ferrer, I., & Pamplona, R. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000091 · Cited by 195 · see citing works
Comparison of 18F-FDG and PiB PET in Cognitive Impairment
Lowe, V. J., Kemp, B. J., Jack, C. R., Senjem, M. L., Weigand, S. D., Shiung, M. S., Smith, G. E., Knopman, D. S., Boeve, B. F., Mullan, B. P., et al. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058529 · Cited by 192 · see citing works
Amyloid PET imaging in patients with mild cognitive impairment: A 2-year follow-up study
Koivunen, J., Scheinin, N., Virta, J. R., Aalto, S., Vahlberg, T., Någren, K., Helin, S., Parkkola, R., Viitanen, M., & Rinne, J. O. (2011) · Neurology · doi:10.1212/wnl.0b013e318212015e · Cited by 188 · see citing works
Characterization of tau positron emission tomography tracer [18F]AV‐1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias
Sander, K., Lashley, T., Gami, P., Gendron, T., Lythgoe, M. F., Rohrer, J. D., Schott, J. M., Revesz, T., Fox, N. C., & Årstad, E. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.01.003 · Cited by 187 · see citing works
Discovery of 6-(Fluoro- 18 F )-3-(1 H -pyrrolo[2,3- c ]pyridin-1-yl)isoquinolin-5-amine ([ 18 F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs)
Walji, A. M., Hostetler, E. D., Selnick, H. G., Zeng, Z., Miller, P. J., Bennacef, I., Salinas, C. A., Connolly, B., Gantert, L. T., Holahan, M. A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00166 · Cited by 181 · see citing works
Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI
Toledo, J. B., Xie, S. X., Trojanowski, J. Q., & Shaw, L. M. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1151-4 · Cited by 180 · see citing works
Levels of Nonphosphorylated and Phosphorylated Tau in Cerebrospinal Fluid of Alzheimer's Disease Patients
Hu, Y., He, S., Wang, X., Duan, Q., Grundke, I., Iqbal, K., & Wang, J. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62554-0 · Cited by 180 · see citing works
Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C‐PIB positron emission tomography study
Archer, H. A., Edison, P., Brooks, D. J., Barnes, J., Frost, C. D., Yeatman, T., Fox, N. C., & Rossor, M. N. (2006) · Annals of Neurology · doi:10.1002/ana.20889 · Cited by 179 · see citing works
Association between genetic traits for immune-mediated diseases and Alzheimer disease
Yokoyama, J. S., Wang, Y., Schork, A. J., Thompson, W. K., Karch, C. M., Cruchaga, C., McEvoy, L. K., Witoelar, A., Chen, C.-H., Holland, D., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0150 · Cited by 176 · see citing works
Diagnosis of Parkinson's Disease Based on Disease-Specific Autoantibody Profiles in Human Sera
Han, M. C., Nagele, E. P., DeMarshall, C. A., Acharya, N. K., & Nagele, R. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032383 · Cited by 175 · see citing works
Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients
Kohnken, R. E., Büerger, K., Zinkowski, R. P., Miller, C., Kerkman, D. J., DeBernardis, J. F., Shen, J., Möller, H., Davies, P., & Hampel, H. J. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01178-2 · Cited by 173 · see citing works
Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease
Perrin, R. J., Craig‐Schapiro, R., Malone, J. P., Shah, A. R., Erdmann-Gilmore, P., Davis, A., Roe, C. M., Peskind, E. R., Li, G., Galasko, D. R., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016032 · Cited by 172 · see citing works
In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease
Villemagne, V. L., Furumoto, S., Fodero‐Tavoletti, M. T., Mulligan, R. S., Hodges, J. R., Harada, R., Yates, P. A., Piguet, O., Pejoska, S., Doré, V., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2681-7 · Cited by 170 · see citing works
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease
Verwey, N. A., van der Flier, W. M., Blennow, K., Clark, C. M., Sokolow, S., Deyn, P. P. D., Galasko, D. R., Hampel, H. J., Hartmann, T., Kapaki, E., et al. (2009) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2009.008232 · Cited by 169 · see citing works
18 F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers
Smith, R., Puschmann, A., Schöll, M., Ohlsson, T., van Swieten, J., Honer, M., Englund, E., & Hansson, O. (2016) · Brain · doi:10.1093/brain/aww163 · Cited by 168 · see citing works
Visinin‐like protein‐1: Diagnostic and prognostic biomarker in Alzheimer disease
Tarawneh, R. M., D’Angelo, G., Macy, E., Xiong, C., Carter, D. R., Cairns, N. J., Fagan, A. M., Head, D. M., Mintun, M. A., Ladenson, J. H., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22448 · Cited by 167 · see citing works
In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia
Burack, M. A., Hartlein, J. M., Flores, H., Taylor-Reinwald, L., Perlmutter, J. S., & Cairns, N. J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c7da8e · Cited by 163 · see citing works
Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers
Iqbal, K., Flory, M. J., Khatoon, S., Soininen, H. S., Pirttilä, T., Lehtovirta, M., Alafuzoff, I. I., Blennow, K., Andreasen, N., Vanmechelen, E., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20639 · Cited by 163 · see citing works
Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant
Mormino, E. C., Brandel, M. G., Madison, C. M., Rabinovici, G. D., Marks, S., Baker, S. L., & Jagust, W. J. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.07.098 · Cited by 158 · see citing works
In VitroCharacterization of Pittsburgh Compound-B Binding to Lewy Bodies
Fodero‐Tavoletti, M. T., Smith, D. P., McLean, C., Adlard, P. A., Barnham, K. J., Foster, L. E., Leone, L., Perez, K. A., Cortés, M., Culvenor, J. G., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0630-07.2007 · Cited by 157 · see citing works
11 C-PIB binding is increased in patients with cerebral amyloid angiopathy–related hemorrhage
Ly, J. V., Donnan, G. A., Villemagne, V. L., Zavala, J. A., Ma, H., O'Keefe, G., Gong, S. J., Gunawan, R. M., Saunder, T., Ackerman, U., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cef7e3 · Cited by 157 · see citing works
A Blood-Based Screening Tool for Alzheimer's Disease That Spans Serum and Plasma: Findings from TARC and ADNI
O’Bryant, S. E., Xiao, G., Barber, R. C., Huebinger, R. M., Wilhelmsen, K. C., Edwards, M., Graff‐Radford, N. R., Doody, R. S., Diaz-Arrastia, R. R., & Initiative, A. D. N. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028092 · Cited by 156 · see citing works
Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease
Sala Frigerio, C., Lau, P., Salta, E., Tournoy, J., Bossers, K., Vandenberghe, R., Wallin, A., Bjerke, M., Zetterberg, H., Blennow, K., et al. (2013) · Neurology · doi:10.1212/01.wnl.0000437306.37850.22 · Cited by 156 · see citing works
Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum
Schneider, P., Hampel, H. J., & Büerger, K. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00104.x · Cited by 151 · see citing works
Radiosynthesis, Photoisomerization, Biodistribution, and Metabolite Analysis of 11C-PBB3 as a Clinically Useful PET Probe for Imaging of Tau Pathology
Hashimoto, H., Kawamura, K., Igarashi, N., Takei, M., Fujishiro, T., Aihara, Y., Shiomi, S., Muto, M., Ito, T., Furutsuka, K., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.139550 · Cited by 151 · see citing works
Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial
Study, T. A. D. C., Grundman, M., Sencakova, D., Jack, C. R., Petersen, R. C., Kim, H. T., Schultz, A. N., Weiner, M., DeCarli, C. S., DeKosky, S. T., et al. (2002) · Journal of Molecular Neuroscience · doi:10.1007/s12031-002-0006-6 · Cited by 150 · see citing works
Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid-β1–42 and τ Proteins as Alzheimer Disease Biomarkers
Kang, J., Korecka, M., Toledo, J. B., Trojanowski, J. Q., & Shaw, L. M. J. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.202937 · Cited by 146 · see citing works
Diagnosis of Alzheimer's Disease Based on Disease-Specific Autoantibody Profiles in Human Sera
Nagele, E. P., Han, M. C., DeMarshall, C. A., Belinka, B. A., & Nagele, R. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023112 · Cited by 146 · see citing works
Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort
Kester, M. I., Teunissen, C. E., Sutphen, C., Herries, E. M., Ladenson, J. H., Xiong, C., Scheltens, P., van der Flier, W. M., Morris, J. C., Holtzman, D. M., et al. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0142-1 · Cited by 146 · see citing works
Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme‐Linked Immunosorbent Assay
Vandermeeren, M., Mercken, M., Vanmechelen, E., Six, J., Voorde, A., Martin, J.-J., & Cras, P. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb09823.x · Cited by 145 · see citing works
Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor and Cognitive Function in Non-Demented Subjects
Li, G., Peskind, E. R., Millard, S. P., Chi, P., Sokal, I., Yu, C., Bekris, L. M., Raskind, M. A., Galasko, D. R., & Montine, T. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005424 · Cited by 144 · see citing works
Meta-Review of CSF Core Biomarkers in Alzheimer’s Disease: The State-of-the-Art after the New Revised Diagnostic Criteria
Ferreira, D., Perestelo‐Pérez, L., Westman, E., Wahlund, L., Sarría‐Santamera, A., & Serrano‐Aguilar, P. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00047 · Cited by 144 · see citing works
Cognition, glucose metabolism and amyloid burden in Alzheimer's disease
Furst, A. J., Rabinovici, G. D., Rostomian, A. H., Steed, T., Alkalay, A., Racine, C. A., Miller, B. L., & Jagust, W. J. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.011 · Cited by 144 · see citing works
Amyloid‐beta plaque growth in cognitively normal adults: Longitudinal [11C]Pittsburgh compound B data
Vlassenko, A. G., Mintun, M. A., Xiong, C., Sheline, Y. I., Goate, A., Benzinger, T. L. S., & Morris, J. C. (2011) · Annals of Neurology · doi:10.1002/ana.22608 · Cited by 144 · see citing works
Autoantibodies to amyloid-? and Alzheimer's disease
Hyman, B. T., Smith, C. R., Buldyrev, I., Whelan, C. M., Brown, H., Tang, M., & Mayeux, R. P. (2001) · Annals of Neurology · doi:10.1002/ana.1061 · Cited by 144 · see citing works
IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment
Prüss, H., Höltje, M., Maier, N., Gomez, A., Buchert, R., Harms, L., Ahnert-Hilger, G., Schmitz, D., Terborg, C., Kopp, U., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318258300d · Cited by 143 · see citing works
Three-dimensional surface mapping of hippocampal atrophy progression from MCI to AD and over normal aging as assessed using voxel-based morphometry
Chételat, G., Fouquet, M., Kalpouzos, G., Denghien, I., De la Sayette, V., Viader, F., Mézenge, F., Landeau, B., Baron, J. C., Eustache, F., et al. (2008) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2007.11.037 · Cited by 143 · see citing works
Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer’s disease
Kadir, A., Marutle, A., Gonzalez, D., Schöll, M., Almkvist, O., Mousavi, M. T., Mustafiz, T., Darreh‐Shori, T., Nennesmo, I., & Nordberg, A. K. (2010) · Brain · doi:10.1093/brain/awq349 · Cited by 139 · see citing works
High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types
Doss, S., Wandinger, K., Hyman, B. T., Panzer, J. A., Synofzik, M., Dickerson, B. C., Mollenhauer, B., Scherzer, C. R., Ivinson, A. J., Finke, C., et al. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.120 · Cited by 136 · see citing works
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects
Toledo, J. B., Zetterberg, H., van Harten, A. C., Glodzik, L., Martinez-Lage, P., Bocchio-Chiavetto, L., Rami, L., Hansson, O., Sperling, R., Engelborghs, S., et al. (2015) · Brain · doi:10.1093/brain/awv199 · Cited by 136 · see citing works
[18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease
Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Hiraoka, K., Watanuki, S., Shidahara, M., Miyake, M., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3035-4 · Cited by 128 · see citing works
Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau
Mori, H., Hosoda, K., Matsubara, E., Nakamoto, T., Furiya, Y., Endoh, R., Usami, M., Shoji, M., Maruyama, S., & Hirai, S. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11291-4 · Cited by 128 · see citing works
Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm
Chiotis, K., Saint‐Aubert, L., Savitcheva, I., Jelić, V., Andersen, P., Jonasson, M., Eriksson, J., Lubberink, M., Almkvist, O., Wall, A. E., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3363-z · Cited by 127 · see citing works
Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI
Landau, S. M., Horng, A., Fero, A., Jagust, W. J., Initiative, A. D. N., Initiative, A. D. N., Weiner, M. W., Aisen, P., Weiner, M. W., Aisen, P., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002576 · Cited by 126 · see citing works
Concordance Between Cerebrospinal Fluid Biomarkers and [11C]PIB PET in a Memory Clinic Cohort
Zwan, M. D., van Harten, A. C., Ossenkoppele, R., Bouwman, F. H., Teunissen, C. E., Adriaanse, S. F., Lammertsma, A. A., Scheltens, P., van Berckel, B. N. M., & van der Flier, W. M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132561 · Cited by 120 · see citing works
No association of CSF biomarkers with APOE 4, plaque and tangle burden in definite Alzheimer's disease
Engelborghs, S., Sleegers, K., Cras, P. P., Brouwers, N., Serneels, S., Leenheir, E. D., Martin, J. J., Vanmechelen, E., Broeckhoven, C. V., & Deyn, P. P. D. (2007) · Brain · doi:10.1093/brain/awm136 · Cited by 113 · see citing works

Flagged first, then by citations

2 of the 296 references couldn’t be matched to a known paper.

Sorted by citations

Imaging Techniques in Alzheimer’s Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring
van Oostveen, W. M., & de Lange, E. C. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042110 · Cited by 297 · see citing works
The Interplay Among Oxidative Stress, Brain Insulin Resistance and AMPK Dysfunction Contribute to Neurodegeneration in Type 2 Diabetes and Alzheimer Disease
Barone, E., Domenico, F. D., Perluigi, M., & Butterfield, D. (2021) · Free Radical Biology & Medicine · doi:10.1016/j.freeradbiomed.2021.09.006 · Cited by 155 · see citing works
Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149 · see citing works
The emerging role of exosomes in Alzheimer’s disease
Zhang, T., Ma, S., Lv, J., Wang, X., Afewerky, H. K., Li, H. R., & Lu, Y. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101321 · Cited by 139 · see citing works
Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer’s disease pathogenesis
Dhiman, K., Blennow, K., Zetterberg, H., Martins, R. N., & Gupta, V. B. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03040-5 · Cited by 114 · see citing works
Early diagnosis and treatment of Alzheimer’s disease: new definitions and challenges
Pais, M. V., Martinez, L. D., Ribeiro, O. G., Loureiro, J. C., Fernandez, R., Valiengo, L. D. C. L., Canineu, P. R., Stella, F., Talib, L. L., Radanovic, M., et al. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2019-0735 · Cited by 118 · see citing works
Human neural stem cell-derived extracellular vesicles mitigate hallmarks of Alzheimer’s disease
Apodaca, L. A., Baddour, A. A. D., Garcia, C., Alikhani, L., Giedzinski, E., Ru, N., Agrawal, A., Acharya, M. M., & Baulch, J. E. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00791-x · Cited by 109 · see citing works
Alzheimer's disease pathophysiology in the Retina
Gaire, B. P., Koronyo, Y., Fuchs, D.-T. S., Shi, H., Rentsendorj, A., Danziger, R., Vit, J., Mirzaei, N., Doustar, J., Sheyn, J., et al. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101273 · Cited by 102 · see citing works
Whole brain imaging reveals distinct spatial patterns of amyloid beta deposition in three mouse models of Alzheimer’s disease
Whitesell, J. D., Buckley, A. R., Knox, J. E., Kuan, L., Graddis, N., Pelos, A., Mukora, A., Wakeman, W., Bohn, P., Ho, A., et al. (2019) · Journal of Comparative Neurology · doi:10.1002/cne.24555 · Cited by 99 · see citing works
An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease
Sun, H., Wang, A., Wang, W., & Liu, C. (2021) · Sensors · doi:10.3390/s21124182 · Cited by 79 · see citing works
Significance of GABAA Receptor for Cognitive Function and Hippocampal Pathology
Sakimoto, Y., Oo, P. M.-T., Goshima, M., Kanehisa, I., Tsukada, Y., & Mitsushima, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212456 · Cited by 75 · see citing works
Exosomal biomarkers in Down syndrome and Alzheimer's disease
Hamlett, E. D., Ledreux, A., Potter, H., Chial, H. J., Patterson, D., Espinosa, J. M., Bettcher, B. M., & Granholm, A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.08.028 · Cited by 78 · see citing works
Plasmonic Nanoparticles as Optical Sensing Probes for the Detection of Alzheimer’s Disease
Oyarzún, M. P., Tapia-Arellano, A., Cabrera, P., Jara-Guajardo, P., & Kogan, M. J. (2021) · Sensors · doi:10.3390/s21062067 · Cited by 62 · see citing works
SOBA: Development and testing of a soluble oligomer binding assay for detection of amyloidogenic toxic oligomers
Shea, D. W., Colasurdo, E. A., Smith, A. S. T., Paschall, C. J., Jayadev, S., Keene, C. D., Galasko, D. R., Ko, A. L., Li, G., Peskind, E. R., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2213157119 · Cited by 59 · see citing works
Association between retinal thickness and β-amyloid brain accumulation in individuals with subjective cognitive decline: Fundació ACE Healthy Brain Initiative
on behalf of the FACEHBI study group, Marquié, M., Valero, S., Castilla-Marti, M., Martínez, J., Rodríguez‐Gómez, O., Sanabria, Á., Tartari, J. P., Monté, G. C., Sotolongo‐Grau, Ó., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00602-9 · Cited by 57 · see citing works
Epilepsy and its neurobehavioral comorbidities: Insights gained from animal models
Löscher, W., & Stafstrom, C. E. (2022) · Epilepsia · doi:10.1111/epi.17433 · Cited by 61 · see citing works
Digital Clock and Recall is superior to the Mini-Mental State Examination for the detection of mild cognitive impairment and mild dementia
Jannati, A., Toro‐Serey, C., Gomes‐Osman, J., Banks, R., Ciesla, M. R., Showalter, J., Bates, D. W., Tobyne, S. M., & Pascual‐Leone, Á. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01367-7 · Cited by 54 · see citing works
Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to
Henriques, A. D., Benedet, A. L., Camargos, E. F., Rosa‐Neto, P., & Nóbrega, O. D. T. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2018.01.002 · Cited by 54 · see citing works
Leveraging hallmark Alzheimer’s molecular targets using phytoconstituents: Current perspective and emerging trends
Dhage, P. A., Sharbidre, A. A., Dakua, S. P., & Balakrishnan, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111634 · Cited by 53 · see citing works
Early Cognitive and Behavioral Deficits in Mouse Models for Tauopathy and Alzheimer’s Disease
Samaey, C., Schreurs, A., Stroobants, S., & Balschun, D. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00335 · Cited by 50 · see citing works
Should artificial intelligence be used in conjunction with neuroimaging in the diagnosis of Alzheimer’s disease?
Mirkin, S., & Albensi, B. C. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1094233 · Cited by 46 · see citing works
Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay
Zhang, L., Du, X., Su, Y., Niu, S., Li, Y., Liang, X., & Luo, H. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01111-z · Cited by 47 · see citing works
Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer’s Disease
Rani, S., Dhar, S. B., Khajuria, A., Gupta, D., Jaiswal, P. K., Singla, N., Kaur, M., Singh, G., & Barnwal, R. P. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01330-y · Cited by 48 · see citing works
Amyloid-β Oligomers: Multiple Moving Targets
Shea, D. W., & Daggett, V. (2022) · Biophysica · doi:10.3390/biophysica2020010 · Cited by 44 · see citing works
Altered cerebral blood flow in older adults with Alzheimer’s disease: a systematic review
Swinford, C. G., Risacher, S. L., Wu, Y., Apostolova, L. G., Gao, S., Bice, P. J., & Saykin, A. J. (2022) · Brain Imaging and Behavior · doi:10.1007/s11682-022-00750-6 · Cited by 44 · see citing works
β-amyloid and Oxidative Stress: Perspectives in Drug Development
Caruso, G., Spampinato, S. F., Cardaci, V., Caraci, F., Sortino, M. A., & Merlo, S. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191209115431 · Cited by 45 · see citing works
Advances in blood biomarkers for Alzheimer disease ( AD ): A review
Assfaw, A. D., Schindler, S. E., & Morris, J. C. (2024) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12870 · Cited by 42 · see citing works
Association between polygenic risk for Alzheimer’s disease, brain structure and cognitive abilities in UK Biobank
Tank, R., Ward, J., Flegal, K. E., Smıth, D. J., Bailey, M. E. S., Cavanagh, J., & Lyall, D. M. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01190-4 · Cited by 42 · see citing works
Neuroimaging-Based Brain Age Estimation: A Promising Personalized Biomarker in Neuropsychiatry
Sone, D., & Beheshti, I. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12111850 · Cited by 41 · see citing works
Innate Immune System Activation and Neuroinflammation in Down Syndrome and Neurodegeneration: Therapeutic Targets or Partners?
Ahmed, M. M., Johnson, N. R., Boyd, T. D., Coughlan, C. M., Chial, H. J., & Potter, H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.718426 · Cited by 41 · see citing works
Ultrasensitive Fluorescence Detection of Alzheimer’s Disease Based on Polyvalent Directed Peptide Polymer Coupled to a Nanoporous ZnO Nanoplatform
Lee, S.-C., Park, H.-H., Kim, S., Koh, S., Han, S.-H., & Yoon, M. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.8b03735 · Cited by 40 · see citing works
Unveiling the Complex Role of Exosomes in Alzheimer’s Disease
Sun, M., & Chen, Z. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s466821 · Cited by 39 · see citing works
Cerebrospinal fluid neuronal pentraxin receptor as a biomarker of long-term progression of Alzheimer’s disease: A 24-month follow-up study
Lim, B., Sando, S. B., Grøntvedt, G. R., Bråthen, G., & Diamandis, E. P. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.03.013 · Cited by 39 · see citing works
Integrative approach of omics and imaging data to discover new insights for understanding brain diseases
Yoon, J. H., Lee, H., Kwon, D., Lee, D., Lee, S., Cho, E., Kim, J., & Kim, D. (2024) · Brain Communications · doi:10.1093/braincomms/fcae265 · Cited by 39 · see citing works
Technical Considerations in Brain Amyloid PET Imaging with 18F-Florbetapir
Trembath, L., Newell, M., & Devous, M. D. (2015) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.115.156679 · Cited by 39 · see citing works
Immune Regulatory Functions of Macrophages and Microglia in Central Nervous System Diseases
Poppell, M., Hammel, G., & Ren, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065925 · Cited by 38 · see citing works
Effect of host genotype and Eimeria acervulina infection on the metabolome of meat-type chickens
Aggrey, S. E., Milfort, M. C., Fuller, A. L., Yuan, J., & Romdhane Rekaya, A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223417 · Cited by 37 · see citing works
Biomarkers for the Diagnosis of Alzheimer’s Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria
Dulewicz, M., Kulczyńska‐Przybik, A., Mroczko, P., Kornhuber, J., Lewczuk, P., & Mroczko, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158598 · Cited by 38 · see citing works
Blood-Derived Plasma Protein Biomarkers for Alzheimer’s Disease in Han Chinese
Cheng, Z., Yin, J., Yuan, H., Jin, C., Zhang, F., Wang, Z., Liu, X., Wu, Y., Wang, T., & Xiao, S. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00414 · Cited by 37 · see citing works
Neuroimaging in Alzheimer's Disease for Early Diagnosis: A Comprehensive Review
Aramadaka, S., Mannam, R., Narayanan, R. S., Bansal, A., Yanamaladoddi, V. R., Sarvepalli, S. S., & Vemula, S. L. (2023) · Cureus · doi:10.7759/cureus.38544 · Cited by 42 · see citing works
Intrinsically disordered proteins in various hypotheses on the pathogenesis of Alzheimer's and Parkinson's diseases
Coskuner‐Weber, O., & Uversky, V. N. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.05.007 · Cited by 35 · see citing works
Brain-Derived Exosomal Proteins as Effective Biomarkers for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Kim, K. Y., Shin, K. Y., & Chang, K. (2021) · Biomolecules · doi:10.3390/biom11070980 · Cited by 35 · see citing works
Transferrin Biosynthesized in the Brain Is a Novel Biomarker for Alzheimer’s Disease
Hoshi, K., Ito, H., Abe, E., Fuwa, T. J., Kanno, M., Murakami, Y., Abe, M., Murakami, T., Yoshihara, A., Ugawa, Y., et al. (2021) · Metabolites · doi:10.3390/metabo11090616 · Cited by 34 · see citing works
A2A Adenosine Receptor as a Potential Biomarker and a Possible Therapeutic Target in Alzheimer’s Disease
Gessi, S., Poloni, T. E., Negro, G., Varani, K., Pasquini, S., Vincenzi, F., Borea, P. A., & Merighi, S. (2021) · Cells · doi:10.3390/cells10092344 · Cited by 35 · see citing works
Metabolomics and Biomarkers for Drug Discovery
Yeung, P. K. F. (2018) · Metabolites · doi:10.3390/metabo8010011 · Cited by 34 · see citing works
Mapping the neuroanatomy of functional decline in Alzheimer’s disease from basic to advanced activities of daily living
Slachevsky, A., Forno, G., Barraza, P., Mioshi, E., Delgado, C., Lillo, P., Henríquez, F., Bravo, E., Farias, M., Muñoz‐Neira, C., et al. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09260-w · Cited by 33 · see citing works
Olfactory response as a marker for Alzheimer’s disease: Evidence from perceptual and frontal lobe oscillation coherence deficit
Sedghizadeh, M. J., Hojjati, H., Ezzatdoost, K., Aghajan, H. K., Vahabi, Z., & Tarighatnia, H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243535 · Cited by 31 · see citing works
Syndecan-3 as a Novel Biomarker in Alzheimer’s Disease
Hudák, A., Letoha, A., Vízler, C., & Letoha, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063407 · Cited by 32 · see citing works
Diagnóstico da doença de Alzheimer: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia
Schilling, L. P., Balthazar, M. L. F., Radanovic, M., Forlenza, O. V., Silagi, M. L., Smid, J., Barbosa, B. J. A. P., Frota, N. A. F., de Souza, L. C., Vale, F. A. C., et al. (2022) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2022-s102pt · Cited by 54 · see citing works
Neuromodulation in the Treatment of Alzheimer’s Disease: Current and Emerging Approaches
Pople, C. B., Meng, Y., Li, D. Z., Bigioni, L., Davidson, B., Vecchio, L. M., Hamani, C., Rabin, J. S., & Lipsman, N. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200913 · Cited by 29 · see citing works
Deep Learning Based Multimodal Progression Modeling for Alzheimer’s Disease
Yang, L., Wang, X., Guo, Q., Gladstein, S., Wooten, D., Li, T., Robieson, W. Z., Sun, Y., Huang, X., & Initiative, F. T. A. D. N. (2021) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2021.1884129 · Cited by 28 · see citing works
Integrated algorithm combining plasma biomarkers and cognitive assessments accurately predicts brain β-amyloid pathology
Pan, F., Huang, Y., Cai, X., Wang, Y., Guan, Y., Deng, J., Yang, D., Zhu, J., Zhao, Y., Xie, F., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00295-9 · Cited by 27 · see citing works
“Previous studies revealed that A β began to accumulate up to 15 – 20 years prior to clinical symptoms of Alzheimer ’ s disease 42,43 .”
A Novel Magnetic Nanoparticle for Early Detection of Amyloid Plaques in Alzheimer's Disease
Zeng, J., Wu, J., Li, M., & Wang, P. (2018) · Archives of Medical Research · doi:10.1016/j.arcmed.2018.09.005 · Cited by 28 · see citing works
Characterization of Inner Retinal Hyperreflective Alterations in Early Cognitive Impairment on Adaptive Optics Scanning Laser Ophthalmoscopy
Zhang, Y. S., Onishi, A. C., Zhou, N., Song, J., Samra, S., Weıntraub, S., & Fawzi, A. A. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.19-27135 · Cited by 27 · see citing works
Diagnosis of Alzheimer’s disease: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology
Schilling, L. P., Balthazar, M. L. F., Radanovic, M., Forlenza, O. V., Silagi, M. L., Smid, J., Barbosa, B. J. A. P., Frota, N. A. F., de Souza, L. C., Vale, F. A. C., et al. (2022) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2022-s102en · Cited by 29 · see citing works
Epigenetic biomarkers in Alzheimer's disease: Diagnostic and prognostic relevance
Behl, T., Kyada, A., Roopashree, R., Nathiya, D., Arya, R., Kumar, M., Khalid, M., Gulati, M., Sachdeva, M., Fareed, M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102556 · Cited by 25 · see citing works
Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer’s disease
Lim, B., Tsolaki, M., Soosaipillai, A., Brown, M., Zilakaki, M., Tagaraki, F., Fotiou, D., Koutsouraki, E., Grosi, E., Prassas, I., et al. (2019) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-0428 · Cited by 25 · see citing works
The Functional Roles and Applications of Immunoglobulins in Neurodegenerative Disease
Sim, K.-Y., Im, K. C., & Park, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155295 · Cited by 24 · see citing works
Assessment of the predictive potential of cognitive scores from retinal images and retinal fundus metadata via deep learning using the CLSA database
Corbin, D., & Lesage, F. (2022) · Scientific Reports · doi:10.1038/s41598-022-09719-3 · Cited by 24 · see citing works
Biomarkers of Parkinson’s Disease: From Basic Research to Clinical Practice
Ma, Z.-L., Wang, Z., Zhang, F., Liu, H. P., Mao, L.-H., & Yuan, L. (2023) · Aging and Disease · doi:10.14336/ad.2023.1005 · Cited by 24 · see citing works
Amyloidogenic Nanoplaques in Blood Serum of Patients with Alzheimer’s Disease Revealed by Time-Resolved Thioflavin T Fluorescence Intensity Fluctuation Analysis
Tiiman, A., Jelić, V., Jarvet, J., Järemo, P., Bogdanović, N., Rigler, R. W., Terenius, L. Y., Gräslund, A., & Vukojević, V. B. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181144 · Cited by 23 · see citing works
Raman Spectrometric Detection Methods for Early and Non-Invasive Diagnosis of Alzheimer’s Disease
Huang, C., & Isidoro, C. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161238 · Cited by 23 · see citing works
Indicators of rapid cognitive decline in amnestic mild cognitive impairment: The role of plasma biomarkers using magnetically labeled immunoassays
Tsai, C., Liang, C., Yang, C., Lee, J., Ho, T., Su, M., Lin, G., Lin, Y., Chu, H., Hsu, Y., et al. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.06.006 · Cited by 23 · see citing works
Mapping cerebral atrophic trajectory from amnestic mild cognitive impairment to Alzheimer’s disease
Wei, X., Du, X., Xie, Y., Suo, X., He, X., Ding, H., Zhang, Y., Ji, Y., Chai, C., Liang, M., et al. (2022) · Cerebral Cortex · doi:10.1093/cercor/bhac137 · Cited by 21 · see citing works
Individualized diagnosis of preclinical Alzheimer's Disease using deep neural networks
Park, J., Jang, S., Gwak, J., Kim, B. C., Lee, J., Choi, K. Y., Lee, K.-H., Sung, C.-J., Jang, G.-J., & Ahn, S.-K. (2022) · Expert systems with applications · doi:10.1016/j.eswa.2022.118511 · Cited by 16 · see citing works
Brain Molecular Connectivity in Neurodegenerative Conditions
Carli, G., Tondo, G., Boccalini, C., & Perani, D. (2021) · Brain Sciences · doi:10.3390/brainsci11040433 · Cited by 19 · see citing works
An Early Detection and Classification of Alzheimer's Disease Framework Based on ResNet-50
Nithya, V. P., Mohanasundaram, N., & Santhosh, R. (2023) · Current Medical Imaging Formerly Current Medical Imaging Reviews · doi:10.2174/1573405620666230825113344 · Cited by 19 · see citing works
Neuroimaging of tissue microstructure as a marker of neurodegeneration in the AT(N) framework: defining abnormal neurodegeneration and improving prediction of clinical status
Gallagher, R. L., Koscik, R. L., Moody, J. F., Vogt, N. M., Adluru, N., Kecskemeti, S., Hulle, C. A. V., Chin, N. A., Asthana, S., Kollmorgen, G., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01281-y · Cited by 19 · see citing works
Demystifying the Role of Neuroinflammatory Mediators as Biomarkers for Diagnosis, Prognosis, and Treatment of Alzheimer’s Disease: A Review
Doke, R. R., Lamkhade, G., Vinchurkar, K., & Singh, S. K. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00457 · Cited by 23 · see citing works
Diagnostic accuracy study of automated stratification of Alzheimer’s disease and mild cognitive impairment via deep learning based on MRI
Chen, X., Tang, M., Liu, A., & Wei, X. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-2961 · Cited by 17 · see citing works
Artificial Intelligence for Alzheimer's disease diagnosis through T1-weighted MRI: A systematic review
Basanta-Torres, S., Rivas-Fernández, M. A., & Galdo-Álvarez, S. (2025) · Comput. Biol. Medicine · doi:10.1016/j.compbiomed.2025.111028 · Cited by 20 · see citing works
Biomarkers of Alzheimer’s Disease and Cerebrovascular Lesions and Clinical Progression in Patients with Subjective Cognitive Decline: A Systematic Review
Scarth, M., Rissanen, I. L., Scholten, R. J. P. M., & Geerlings, M. I. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210218 · Cited by 18 · see citing works
Early Detection and Treatment of Patients with Alzheimer’s Disease: Future Perspectives
Guest, F. L. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-05542-4_15 · Cited by 17 · see citing works
Aplicaciones de aprendizaje automático en salud
Aracena, C., Villena, F., Arias, F., & Dunstan, J. (2022) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2022.10.001 · Cited by 16 · see citing works
Self-powered sensors for biomarker detection
Li, J., Xu, L., Zou, Y., & Li, Z. (2023) · Sensors & Diagnostics · doi:10.1039/d3sd00050h · Cited by 15 · see citing works
Amyloid detection in neurodegenerative diseases using MOFs
Maru, K., Singh, A., Jangir, R., & Jangir, K. K. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb00373j · Cited by 16 · see citing works
Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF‐AD study
Smith, R. G., Pishva, E., Kouhsar, M. P., Imm, J. L., Dobričić, V., Johannsen, P., Wittig, M., Franke, A., Vandenberghe, R. R., Schaeverbeke, J. M., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14098 · Cited by 15 · see citing works
Detection of Alzheimer’s disease using grey wolf optimization based clustering algorithm and deep neural network from magnetic resonance images
Suresha, H. S., & Parthasarathy, S. S. (2021) · Distributed and Parallel Databases · doi:10.1007/s10619-021-07345-y · Cited by 16 · see citing works
Beyond the amyloid hypothesis: how current research implicates autoimmunity in Alzheimer’s disease pathogenesis
Chatanaka, M. K., Sohaei, D., Diamandis, E. P., & Prassas, I. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2187342 · Cited by 15 · see citing works
Survival Analysis in Cognitively Normal Subjects and in Patients with Mild Cognitive Impairment Using a Proportional Hazards Model with Extreme Gradient Boosting Regression
Khajehpiri, B., Initiative, A. D. N., Moghaddam, H. A., Forouzanfar, M., Lashgari, R., Ramos-Cejudo, J., Osorio, R. S., & Ardekani, B. A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215266 · Cited by 15 · see citing works
Reduced parietal activation in participants with mild cognitive impairments during visual-spatial processing measured with functional near-infrared spectroscopy
Haberstumpf, S., Seidel, A., Lauer, M., Polak, T. T., Deckert, J., & Herrmann, M. J. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.12.021 · Cited by 15 · see citing works
Confinement-guided ultrasensitive optical assay with artificial intelligence for disease diagnostics
Zhang, W., Lu, Y., Su, C., Wang, Y., Wang, Y., Zhang, B., Jiang, C., Guo, K., & Xu, C. S. (2023) · The Innovation Medicine · doi:10.59717/j.xinn-med.2023.100023 · Cited by 15 · see citing works
Effects of physical activities on dementia‐related biomarkers: A systematic review of randomized controlled trials
Moniruzzaman, M., Kadota, A., Akash, M. S., Pruitt, P. J., Miura, K., Albin, R. L., & Dodge, H. H. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12109 · Cited by 16 · see citing works
Ethical Frameworks for Disclosure of Alzheimer Disease Biomarkers to Research Participants: Conflicting Norms and a Nuanced Policy
Bunnik, E. M., Smedinga, M., Milne, R., Georges, J., Richard, E., & Schermer, M. (2022) · Ethics & Human Research · doi:10.1002/eahr.500146 · Cited by 14 · see citing works
What traditional neuropsychological assessment got wrong about mild traumatic brain injury. II: limitations in test development, research design, statistical and psychometric issues
Bigler, E. D., Allder, S. J., & Victoroff, J. (2024) · Brain Injury · doi:10.1080/02699052.2024.2376261 · Cited by 14 · see citing works
Plasma amyloid-beta levels correlated with impaired hepatic functions: An adjuvant biomarker for the diagnosis of biliary atresia
Lyu, H., Ye, Y., Lui, V. C. H., Wu, W., Chung, B., Wong, K. K. Y., Li, H., Wong, M. S., Tam, P. K. H., & Wang, B. (2022) · Frontiers in Surgery · doi:10.3389/fsurg.2022.931637 · Cited by 14 · see citing works
Identification of Blood-Based Glycolysis Gene Associated with Alzheimer’s Disease by Integrated Bioinformatics Analysis
Wang, F., Xu, C., Chen, W., Duan, S., Xu, S., Dai, J., & Wang, Q. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210540 · Cited by 13 · see citing works
Neural Oscillation Disorder in the Hippocampal CA1 Region of Different Alzheimer's Disease Mice
Yuan, W., Zhi, W., Ma, L., Hu, X., Wang, Q., Zou, Y., & Wang, L. (2023) · Current Alzheimer Research · doi:10.2174/1567205020666230808122643 · Cited by 15 · see citing works
Explainable Artificial Intelligence (XAI) on Neurogenerative Diseases
Gaur, L., & Gaur, D. (2024) · Studies in computational intelligence · doi:10.1007/978-3-031-53148-4_3 · Cited by 14 · see citing works
Multifaceted roles of extracellular vesicles in the interplay of neuroinflammation and neurodegenerative diseases
Deng, Z., Chen, H., Chen, J., Du, Z., Zhou, W., & Yuan, Z. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167960 · Cited by 13 · see citing works
Prediction of amyloid PET positivity via machine learning algorithms trained with EDTA-based blood amyloid-β oligomerization data
Youn, Y. C., Kim, H. R., Shin, H.-W., Jeong, H.-B., Han, S., Pyun, J., Ryoo, N., Park, Y. H., & Kim, S. (2022) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-022-02024-z · Cited by 12 · see citing works
Plasma biomarkers of Alzheimer's disease and related dementias in American Indians: The Strong Heart Study
Suchy‐Dicey, A. M., Longstreth, W. T., Rhoads, K., Umans, J. G., Buchwald, D., Grabowski, T. J., Blennow, K., Reiman, E. M., & Zetterberg, H. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13664 · Cited by 12 · see citing works
Rationale and design of the BeyeOMARKER study: prospective evaluation of blood- and eye-based biomarkers for early detection of Alzheimer’s disease pathology in the eye clinic
Bader, I., Groot, C., Tan, H. S., Milongo, J.-M. A., den Haan, J., Verberk, I. M. W., Yong, K. X. X., Orellina, J. A., Campbell, S. R., Wilson, D., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01545-1 · Cited by 12 · see citing works
Proteomics and Neurodegenerative Disorders: Advancements in the Diagnostic Analysis
Puranik, N., Yadav, D., Yadav, S. K., Chavda, V. K., & Jin, J. (2020) · Current Protein and Peptide Science · doi:10.2174/1389203721666200511094222 · Cited by 12 · see citing works
Associations between cerebrospinal fluid markers and cognition in ageing and dementia: A systematic review
Saunders, T. S., Gadd, D. A., Spires‐Jones, T. L., King, D., Ritchie, C. W., & Terrera, G. M. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15656 · Cited by 12 · see citing works
A Comprehensive Review of Modifiable Cardiovascular Risk Factors and Genetic Influences in Dementia Prevention
Khan, M. B., Jaiswal, A., & Wandile, B. V. (2023) · Cureus · doi:10.7759/cureus.48430 · Cited by 11 · see citing works
Pvtad: Alzheimer’s Disease Diagnosis Using Pyramid Vision Transformer Applied to White Matter of T1-Weighted Structural Mri Data
Aghdam, M. A., Bozdag, S., Saeed, F., & Initiative, A. D. N. (2024) · IEEE International Symposium on Biomedical Imaging (ISBI) · doi:10.1109/isbi56570.2024.10635541 · Cited by 11 · see citing works
An interpretable deep learning framework identifies proteomic drivers of Alzheimer’s disease
Panizza, E., & Cerione, R. A. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1379984 · Cited by 11 · see citing works
Imaging asparaginyl endopeptidase (AEP) in the live brain as a biomarker for Alzheimer’s disease
Wang, S., Liu, Z., Liu, J., Cheng, Q., Wang, Y., Liu, Y., Ni, W.-W., Chen, H., & Song, M. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00988-0 · Cited by 11 · see citing works
Artificial Intelligence in Neuro Degenerative Diseases: Opportunities and Challenges
Rajaraman, S. (2024) · Studies in computational intelligence · doi:10.1007/978-3-031-53148-4_8 · Cited by 10 · see citing works

Correspondence to:
Dubravka, M. B., Dorotea, Š. Š., Stanić, G., Patrick, R., Šimić, H. G., Brain, F., & Šimić, G. (2014)
Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease
Leko, M. B., Štrac, D. Š., Mück‐Šeler, D., Pivac, N., Stanić, G., Hof, P. R., & Šimić, G. (2014) · Croatian Medical Journal · doi:10.3325/cmj.2014.55.347 · Cited by 46 · see citing works
Biomarkers of Alzheimer Disease
Sperling, R. A., & Johnson, K. A. (2013) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000429181.60095.99 · Cited by 55 · see citing works
Biomarkers in the Early Detection and Diagnosis of Alzheimer's Disease
Rucka, A. M., Kowalski, M., Rucki, M., Cieleban, N., Gajewska, M., & Modliborska, M. (2026) · Journal of Education Health and Sport · doi:10.12775/jehs.2026.94.73121
Role of CSF Biomarkers in the Diagnosis of Prodromal Alzheimer‘s Disease
Parnetti, L., & Chiasserini, D. (2011) · Biomarkers in Medicine · doi:10.2217/bmm.11.48 · Cited by 12 · see citing works

Authors: Counts, S. E., Ikonomovic, M. D., Mercado, N., Vega, I. E., & Mufson, E. J.
Affiliations: Trinity Health Grand Rapids (US)
Michigan State University (US)
Barrow Neurological Institute (US)
Corresponding author: Mufson, Elliott J.
ORCID: Counts, Scott E.
Vega, Irving E.
Mufson, Elliott J.
Venue: Neurotherapeutics
Publisher: Elsevier BV
Published: 2017-01
Volume: 14
Issue: 1
Pages: 35-53
ISSN: 1878-7479 (ISSN-L)
DOI: 10.1007/s13311-016-0481-z
PMC: PMC5233625
OpenAlex: W2529983878
Cited by: 224
References: 296
Citations by year: 2026: 23 · 2025: 25 · 2024: 35 · 2023: 27 · 2022: 24 · 2021: 33 · 2020: 22 · 2019: 18 · 2018: 11 · 2017: 3 · 2016: 2 · 2015: 1
FWCI: 1.62
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: other-oa
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 2423 d)
Locations: Neurotherapeutics (publishedVersion, other-oa)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute on Aging (AG043375, AG026032)
National Intitute on Aging (AG042146)
BNI Barrow and Beyond
Saint Mary’s Foundation
Miles for Memories of Battle Creek
National Insitute of Aging (PO1AG025204)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
Keywords: Alzheimer's disease, biomarkers, early detection, preclinical Alzheimer's disease, disease progression, cerebrospinal fluid biomarkers, amyloid-beta 42, total tau, phosphorylated tau, amyloid PET, tau PET, FDG-PET, blood biomarkers
MeSH terms: Alzheimer Disease, Autoantibodies, Humans, Sensitivity and Specificity, Biomarkers, Amyloid beta-Peptides, Disease Progression, Inflammation Mediators, Early Diagnosis, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Biomarkers for the Early Detection and Progression of Alzheimer's Disease

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks